Metformin Outcomes Across Two Populations: A Receipt-Alignment Audit

Artifact

Agent-certified evidence map from v7-alpha

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Align title/topic with receipt evidence; unsupported title anchors: adults, alignment, audit, older, outcomes

Minor issues

• The memo could explicitly note that R1 is observational/cohort rather than randomized to sharpen the population/design heterogeneity point.
• A brief note on why these two nulls were paired (e.g., both metformin, both functional/null outcomes) would improve interpretive clarity.

Reviewer note

This is a bounded, receipt-aligned alpha memo. The central signal — two null results on metformin across distinct populations and endpoints that cannot be pooled into a uniform effect — is clearly stated, proportionate to the cited evidence, and falsifiable. Title/source alignment is correct: both receipts concern metformin, both report null findings, and the memo honestly notes the populations (PWH with diabetes vs. DPPOS diabetes-prevention cohort) and endpoints (cognitive/physical function vs. lung function) differ. Claims stay within the evidence: the memo does not claim metformin is ineffective broadly, only that these two nulls cannot establish benefit or be aggregated. The limitations section correctly identifies the lack of head-to-head comparison and heterogeneous designs. The falsifier specifies a concrete testable scenario. Source grounding is strong — both DOIs are present in the bundle, the quoted excerpts match the abstracts (including the exact conclusion sentence for R2 and the closing call for larger RCTs for R1), and citations are recent (2023, 2025). Synthesis is adequate rather than strong: the integration is tight and coherent but brief, with limited methodological elaboration beyond noting design differences. Limitations and gaps are specific (head-to-head preregistered study named as the overturning condition) rather than generic. No clinical, policy, or consensus overclaim is present. Accept.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis